Invokana Lawsuit News: New Analysis Details Rising Incidence of Ketoacidosis among Users of SGLT2 Inhibitor Diabetes Drugs, Bernstein Liebhard LLP Reports

February 01, 2016 (PRLEAP.COM) Business News
February 1, 2016 - The U.S. Food & Drug Administration (FDA) continues to receive adverse event reports involving SGLT2 inhibitors, such as Invokana, and diabetic ketoacidosis. According to the most recent QuarterWatch report issued by the Institute for Safe Medication Practices (ISMP), the agency's adverse event database received 168 such reports involving Invokana during the 12-month period ending June 30, 2015. During the same time period, the database logged 80 cases involving Farxiga and 12 reports associated with Jardiance. The ISMP was unable to estimate the incidence of ketoacidosis among patients using Invokana, Farxiga or Jardiance, as it is not known how many cases go unreported.

"In the past year, the FDA has issued two safety alerts regarding ketoacidosis and SGLT2 inhbitiors. Our Firm has since received a number of inquiries from patients who allegedly suffered this serious complication while using one of these medications to treat Type 2 diabetes. We are not surprised that the FDA continues to receive these types of reports," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating product liability claims on behalf of Type 2 diabetes patients who developed ketoacidosis allegedly related to the use of Invokana and other SGLT2 inhibitors.

SGLT2 Inhibitor and Diabetic Ketoacidosis
Invokana, Jardiance, Farxiga and other SGLT2 inhibitors are approved to lower blood sugar in patients with Type 2 diabetes. In May 2015, the FDA announced that it was investigating 20 reports of diabetic ketoacidosis that had occurred in individuals taking SGLT2 inhibitors. While some patients had been using the medications to treat Type 1 diabetes (an off-label use), a number of the ketoacidosis reports involved patients undergoing treatment for Type 2 diabetes. While ketoacidosis is often associated with Type 1 diabetes, it is unusual in patient with Type 2.

On December 4th, the FDA announced that new information regarding a potential association with diabetic ketoacidosis would be included on the labels for Invokana and other SGLT2 inhibitors. The alert indicated that from March 2013 to May 2015, the FDA had identified 73 cases of ketoacidosis in patients with Type 1 or Type 2 diabetes treated with SGLT2 inhibitors.

Diabetic ketoacidosis occurs when dangerous levels of toxic acids called ketone accumulate in the body. The condition can lead to hospitalization, diabetic coma and even death. "Patients should stop taking their SGLT2 inhibitor and seek medical attention immediately if they have any symptoms of ketoacidosis, a serious condition in which the body produces high levels of blood acids called ketones. Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing," the FDA said in its December 4th communication.

Patients who used Invokana or another SGLT2 inhbitor may be entitled to compensation if they were hospitalized with ketoacidosis while undergoing treatment. To learn more about filing an Invokana lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share Article